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Abstract
Background: The aim of this study was to evaluate, the existence of a signature of differentially expressed
microRNAs (miRNAs) during osteogenic differentiation of bone marrow MSCs from OA and healthy donors and
to describe their possible implication in joint regeneration through modulation of molecular mechanisms involved
in homeostatic control in OA pathophysiology.
Methods: Following phenotypic assessment of BM-MSCs obtained from OA diagnosed patients (n = 10) and
non-OA (n = 10), total small RNA was isolated after osteogenic induction for 1, 10 and 21 days, miRNA profiles
were generated using a commercial expression array of 754 well-characterized miRNAs. MiRNAs, with consistent
differential expression were selected for further validation by quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) analysis.
Results: A total of 246 miRNAs were differentially expressed (fold change ≥ ± 2, P ≤0.05) between OA and non-OA
BM-MSC samples; these miRNAs showed variable interactions depending on the cell and differentiation status.
Two miRNAs, hsa-miR-210 and hsa-miR-335-5p out of 21 used for validation showed a significant downregulated
expression during induced osteogenesis. In particular hsa-miR-335-5p, a critical regulator in bone homeostasis,
was further studied. hsa-miR-335-5p downregulation in OA-MSCs, as well as their host coding gene, MEST,
were also assessed.
Conclusions: To our knowledge, this study represents the most comprehensive assessment to date of miRNA
expression profiling in BM-MSCs from OA patients and their role during osteogenic differentiation. We describe
the existence of a correlation between miR-335-5p expression and OA indicating the putative role of this
miRNA in OA features. These findings, may contribute to our understanding of the molecular mechanisms involved
in MSCs mediated homeostatic control in OA pathophysiology that could be applicable in future therapeutic approaches.
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Background
Osteoarthritis (OA) is a common musculoskeletal dis-
order with high socioeconomic impact [1]. It is charac-
terized by alterations in bone-cartilage homeostasis
leading to progressive degeneration of synovial joints [2].
OA etiology is largely unknown; however it has been
associated to susceptibility factors such as age, prior
joint injury and other alterations linked to genetic and
epigenetic factors [3, 4]. Currently, no cure exists for
OA, beyond pain relief. In this context, cell therapies are
being studied as an alternative for OA treatment [5].
Therapeutic approaches using MSCs (Mesenchymal
Stem in Cells) are considered one of the best options for
future treatment of damaged OA cartilage and bone.
This approach is based on the potential of MSCs to
differentiate into chondrocytes and osteoblasts and their
immunomodulatory properties.
Biochemical mechanisms involved in OA initiation
and progression are modulated by a fine-tuned crosstalk
between different signaling pathways, most of them
converging in the WNT signaling pathway [6]. WNT
signaling is involved into a range of biological processes
essential for maintenance of joint homeostasis, including
cell proliferation, cell-fate determination and differenti-
ation [7–9]. In addition to cell signaling, another
important regulatory mechanism of cell function is the
post-transcriptional modulation of gene expression by
microRNAs (miRNAs), a family of small noncoding
RNAs. MiRNAs have been described as important
players interfering in the expression of multiple target
genes and thus modulating their biological functions,
e.g. chondrogenesis and osteogenesis [10–12].
Dysfunction of canonical Wnt/β-catenin signaling has
been implicated in OA pathogenesis [13]. A number of
components including Wnts, frizzled, secreted frizzled-
related protein (sFRP), Dickkopf and LRPs (LDL-receptor-
related protein) play crucial roles during cartilage and bone
development and joint maintenance. Moreover, increased
levels of β-catenin have been observed in degenerative
cartilage, suggesting that continuous Wnt signaling might
contribute to cartilage loss. This evidence was supported by
the fact that a polymorphism in the SFRP3 is associated
with a reduced ability to limit β-catenin signaling and with
an increased susceptibility to OA development [14].
Together, these evidences suggest that deregulation of
signaling pathways by miRNAs and their relationship
may provide clues to understand the OA pathogenesis.
Indeed, Wnt β-catenin signaling pathway has been
described to be susceptible of modulation by targeted
repression of translation of specific pathway components
[15, 16]. For example, increased expression levels of
miR-335-5p regulate bone development promoting
osteogenic differentiation by downregulating DKK1 and
thus activating Wnt signaling [17]. On the other hand,
some miRNAs are also specifically expressed under
regulation of Wnt/β-catenin in a regulatory feedback
loop [18, 19]. Moreover, tissue damage or proinflamma-
tory signals may also cause miR-335 downregulation
which in turn activates the proliferative, migratory and
differentiation capacities of MSCs [20].
Given that miRNAs are important post-transcriptional
regulators of gene expression, variations in miRNA
expression levels are likely involved in molecular changes
occurring during joint formation and/or remodeling [21].
To describe the role of miRNAs in OA pathophysiology,
we aimed to evaluate the existence of a differential
expression signature of miRNAs in bone marrow MSCs
comparing OA and healthy donors during in vitro induced
osteogenesis. This knowledge is essential, both for better
understand the regulatory mechanisms taking place in OA
pathophysiology and for development of new therapeutic
approaches based in selective targeting of key molecules.
Methods
Patients and specimens
Bone marrow aspirates were obtained from patients
undergoing total hip arthroplasty of OA patients (n = 10)
(71.2 ± 9.2 years) and control subjects (n = 10) with
femoral neck fracture (82.0 ± 9.5 years). OA diagnosis
was established according to the ACR criteria [22].
Control subjects, evaluated by an independent observer,
did not show OA radiographic changes and their clinical
records did not evidenced signs of osteoporosis assessed
by densitometric T-score > −2.5 SD. All samples were
processed after written informed consent was obtained.
The study was approved by our institutional ethics
committee (CEIC Hospital Clínico San Carlos) according
to the principles expressed in the Declaration of Helsinki.
BM-MSCs cell cultures
MSCs were obtained from 5 to 10 ml of bone marrow
aspirates. Briefly, each aspirate was diluted 1:1 with
Dulbecco’s modified Eagle’s medium (DMEM) (Promocell
GmbH, Heilderberg, Germany) and layered over an equal
volume of Ficoll. After centrifugation, at 900 × g for 30 min,
the mononuclear cell layer was recovered, washed with
DMEM, and re-suspended in DMEM supplemented with
10 % fetal bovine serum 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine. The cultures were
washed to remove the non-adherent cells and further
expanded until approximately 80 % confluence. Cells at
confluence were detached with 0.25 % trypsin-EDTA for
5 min at 37 °C and replated for continued passaging at
dilution 1:2. Cells at the third passage were used for
experiments.
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BM-MSCs characterization by flow cytometry and lineage
multipotential
Phenotypic characterization of isolated MSCs was
performed by flow citometry in a Gallios flow cytometer
(Beckman Coulter). Cells recovered at the third passage
were washed with PBS prior incubation during 30 min at
4 °C with specific phycoerythrin conjugated antibodies
and their isotype matched antibodies (all from Miltenyi
Biotech). Expression of CD105, CD73 and CD90, and lack
of expression of CD45, CD34, and CD14 were the
minimal criteria required prior to evaluation of their
differentiation potential towards chondrogenic, adipogenic
and osteogenic lineages, assessed by histochemical
stainings.
Induction of osteogenic, adipogenic and chondrogenic
differentiation
Cultures for histochemical analysis were performed in
24-well tissue culture plates at a seeding density of
(30,000 cells/cm2) using commercial culture media with
supplements according to manufacturer instructions
(Promocell Cat# C-28013 for osteogenesis, Cat# C-28012
for chondrogenesis and Cat# 28011 for adipogenesis).
The degree of mineralization in osteogenic cultures
was assessed after staining for 20 min with 2 % Alizarin
red S (Sigma). Adipogenic lineage commitment was
evaluated in adipogenic induced cultures, by staining for
5 min with an Oil red O working solution (3 parts of
0.5 % Oil Red O in isopropanol diluted with 2 parts of
distilled water). Chondrogenic potential was evaluated by
measuring proteoglycan synthesis in chondrogenic
induced cultures. Staining was performed for 20 min with
1 % Alcian Blue. Visualization of cells was performed
under phase contrast microscopy (Leica 4000b DMI,
Leica. Germany).
Extraction of miRNAs and microarray analysis
Total small RNA was recovered at days 1, 10 and 21 of
osteogenically induced MSCs. RNA was solated using the
mirVana PARIS kit (Ambion, Grand Island, NY, USA)
according to the manufacturer’s instructions. MiRNA
quality was assessed using Agilent’s 2100 bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). Total
miRNA profiles were generated using an ABI Taqman
OpenArray MicroRNA pools A and B to measure the
expression of 754 well-characterized miRNA sequences
from the Sanger miRBase v14.
Briefly, total small RNA isolated from cells was divided
equally for each sample and used with TaqMan Megaplex
RT primer pools A or B to generate cDNA which was
subsequently amplified using the corresponding Megaplex
PreAmp Primers (pools A or B, respectively) following the
manufacturer’s instructions. Real-time PCR was performed
on the Taqman Open Array MicroRNA plates using the
Applied Biosystem Open Array Real-Time PCR system.
Data were further exported for analysis (included in
Additional file 1).
Total RNA isolation, cDNA synthesis and RT-PCRs
For miRNA RT-PCR, total RNA was isolated with
miRCURY isolation kit (Exiqon) and cDNA Synthesis
was carried out using 10 ng of RNA and the Universal
cDNA synthesis kit II (Exiqon). Following reverse
transcription, cDNAs were 1:100 diluted and loaded
onto the real time PCR plates using a 1:1 mixture of
Exilent SYBR Green master mix 2× (Exiqon). Real Time
PCR reactions were performed in a 7900HT Fast Real
time PCR System (Applied Biosystems) under the
following conditions: 95 °C 10 min, 45 cycles of 95 °C
10s and 60 °C 1 min. After run completion, Ct values
were calculated using the SDS 2.4 software (Applied
Biosystems) and data were analyzed using the StatMiner®
software (Integromics). The data sets supporting the results
of this article are available in the GEO repository, http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70856.
Total RNA was isolated from cultured cells with a
miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). Human
miR-335 and MEST, were quantified by real-time RT-PCR
using the corresponding TaqMan Gene Expression Assays
(Applied Biosystems, Foster City, CA, USA). RNU6B and
GAPDH were used as endogenous normalization controls
for miRNAs and MEST, respectively.
For PCR amplification of DKK1 and SFRP1, RNA from
cultures was pre-amplified using the RT2 Nano PreAMP
cDNA Synthesis Kit (Cat# C06, SABiosciences, Qiagen).
cDNA conversion was performed with the Maxima H
Minus Kit (Cat#K1682. Fermentas) and the Maxima Sybr/
R QPCR kit (Cat# K0221. Fermentas) was used for PCR
amplification in a Mastercycler realplex4 (Eppendorf)
using the following conditions: 95 °C, 10 min; 40 cycles of
(95 °C, 15 s; and 60 °C, 60 s). Forward and Reverse primer
sequences used were respectively: ACTB (β-actin), 5′-
CGC CCC AGG CAC CAG GCG-3′; 5′-GCT GGG
GTG TTG AAG GT-3′. DKK1: 5′-GTG CAA ATC TGT
CTC GCC TG-3′; 5′-GCA CAG TCT GAT GAC CGG
AG-3′ and SFRP1: 5′-TTT GAG GAG AGC ACC CTA
GGC-3′; 5′-TGT GTA TCT GCT GGC AAC AGG-3′.
ACTB was used as internal reference gene. Amplification
of the relevant amplicon sizes (284, 266 and 75 bp respect-
ively) was confirmed by electrophoresis on a 2 % agarose
gel stained with Midori Green (Nippon Genetics Europe
GmbH) and visualized under ultraviolet light.
Data analysis and statistical methods
Microarray data preprocessing was done with the R
programming language. MiRNAs with Ct values higher
than 35 were considered as undetected. Data were
normalized using a mean-centering restricted (MCR)
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strategy as described by Wylie et al. [23], which uses
miRNAs expressed in all samples for data normalization.
The mean of these fully expressed miRNAs in a given
sample is subtracted from all miRNAs in that sample. After
normalization, statistical analysis was performed via custom
scripts based on the R/Bioconductor package LIMMA
(Linear Models for Microarray) [24]. Comparisons between
experimental groups were performed using a moderated
t-test from LIMMA and P-values were adjusted for
multiple testing using the Benjamini-Hochberg method
[25]. Adjusted P-values < 0.05 were considered statistically
significant. Unless specified, median and interquartile rank
(IQR) values were calculated. P values less than 0.05 were
considered significant. Data were analyzed using Graph-
Pad Prism 6.01 (GraphPad Software, San Diego, CA).
Results
Characterization of bone marrow MSCs
The phenotypic uniformity of BM-MSCs used in the
study was assessed according to several minimal criteria:
these include the plastic-adherence in culture, positivity
for expression of CD90, CD73, CD105 and absence of
hematopoietic surface markers CD34, CD45 and CD14
expression and their osteogenic and chondrogenic
lineage potential. The expression pattern of the cells
used was similar in all samples (Fig. 1a and b) In
addition, the multilineage differentiation potential of
MSCs used in the study was evaluated. All samples were
able to differentiate into osteogenic, chondrogenic and
adipogenic lineages under the appropriate stimulatory
conditions (Fig. 1a and b).
MiRNA expression profiles during osteogenic induction
using microarray
To address the hypothesis that OA- or Control-MSCs
have a different epigenetic signature of miRNAs during
osteogenic differentiation. Expression levels of 754
miRNAs were assessed using miRNA microarray expres-
sion chips. Raw data were preprocessed and filtered
using R routines. A total of 246 miRNAs with at least
two observations for each combination of status (OA or
Control) and differentiation days (t = 0, 10, 21) were
further processed. The variability introduced by single
individuals was detected using statistical random effects
models. Given that no significant effect was detected,
data were finally analyzed using fixed effect models.
Combinations of variables which best explained the data
were detected after a linear discriminant analysis (LDA).
Four miRNAs; hsa-miR-197, hsa-miR-320, hsa-miR-616
and hsa-miR-99b_ showed differences during differenti-
ation indicating the existence of an interaction between
status and differentiation variables (Additional file 2). On
the other hand, 15 miRNAs did not show any inter-
action (that is, were independent of cell status) but
showed differences during osteogenic progression
(Additional file 3). Similarly, 30 miRNAs were inde-
pendent during differentiation times analyzed but
showed differences between OA and control samples
Fig. 1 Characterization of BM-MSCs by Flow Citometry and in vitro
potential of differentiation. Representative flow Cytometry analysis of
bone marrow MSCs obtained from one Control (non-OA) donor (a).
and one osteoarthritic patient (b). MSCs at third passage were positive
for MSC specific markers (CD90, CD73, CD105 and negative for CD34,
CD45 and CD14). Figure represents an overlay image of antibody
isotype controls (light gray histogram) and specific marker antibodies
(dark gray histogram). Histochemical staining of In vitro potential of
differentiation through the adipogenic, chondrogenic and osteogenic
lineages measured at day 21 (adipogenesis and osteogenesis) or 28
(chondrogenesis) for Control BM-MSCs (a, b and c respectively) and OA
BM-MSCs (d, e and f). Magnification × 100
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(Additional file 4). However, although all the differences
noted were statistically significant after multiple test
correction this significance was lost. The data set sup-
porting these results are included in Additional file 1.
MiRNA validation by quantitative PCR
A set of miRNAs with consistent differential expression
in our microarray was further validated by q-PCR. This
included a total of 21 miRNAs selected according to
their lower q values (Table 1). Distribution of miRNAs
analyzed and their overlapping among different compari-
sons are provided in Additional file 5.
Two miRNAs, hsa-miR-210 and hsa-miR-335-5p out
of the 21 used for validation showed a significative
downregulated expression during osteogenesis. More
specifically, hsa-miR-210 expression pattern was quite
similar in OA and control MSCs, which is reflected by an
average downregulation of 5.5 times between days [0–10]
and 9.5 times between days [0–21]. A downregulatory
trend also occurs during osteogenesis for miR-335-5p,
which was down-regulated an average of 2 and 12 fold
respectively, although not significant in the case of OA-
MSCs (Fig. 2).
BM-MSCs from OA patients express lower levels of miR-
335 than control subjects
Current findings have described miR-335 as a critical
regulator in bone homeostasis and MSCs commitment.
Besides, it has also been described that expression levels
of mature miR-335 in human MSCs correlate with those
of its host coding-gene MEST (mesoderm-specific
transcript homolog). Therefore, we aimed to determine
whether expression of miR-335-5p correlated with OA
status measuring the expression of miR-335-5p and
Table 1 miRNAs with consistent differential expression in the
microarray and their target sequences, validated by q-PCR. This
included a total of 21 miRNAs selected according to their lower
q values
























Fig. 2 Relative Quantification of comparisons between t = 10
and t = 0; t = 21 and t = 0 of significant miRNAs in OA-MSCs and
Control-MSCs. Expression of miR210 and miR-335-5p follow a similar
downregulation trend during osteogenic differentiation of MSCs,
both in OA (n = 5) or in Control subjects (n = 3). Project was normalised
using: hsa-miR-103a-3p; hsa-miR-191-5p; hsa-miR-30c-5p; SNORD49A.
Test Type used: Parametric test (Limma). FDR method: Benjamini-Hochberg
Adjusted p-value threshold: 0.05
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MEST in undifferentiated BM-MSC populations from
OA and control subjects.
Our results showed lower expression levels of miR-335
in BM-MSCs obtained from OA donors (Fig. 3a).
Additionally, although a positive correlation between
miR-335-5p and MEST expression was detected
(Spearman correlation coefficient, r = 0.59; p = 0.0961
in OA and r = 0.6; p = 0.0968 in controls) MEST
expression was similar between OA and control MSCs
(Fig. 3b). These results clearly indicated that down-
regulation of miR-335-5p was an inherent feature of
OA-MSCs.
Wnt antagonists DKK1 and SFRP1 are not differentially
inhibited by miR-335-5p
Increased bone formation is one of the main OA features.
In addition osteoinduction through Wnt signaling can be
promoted by inhibition of Wnt antagonists such as DKK1
and SFRP1, two known predicted targets of miR-335-5p.
We next aimed to confirm if differential expression of
miR-335-5p in OA-MSCs correlated with a reduced
expression of: DKK1 and SFRP1. Our data revealed that
independently of miR-335-5p expression, mRNA levels of
antagonists were similar both in undifferentiated OA- or
Control-MSCs (Fig. 4).
Discussion
Bone homeostasis, which largely depends on the appro-
priate differentiation of chondro- and osteo-progenitor
MSCs, is susceptible of disturbances leading to skeletal
dysplasias or articular diseases such as osteoarthritis
[26], however it has been described that during OA
progression bone marrow OA-MSCs exhibit different
properties that from healthy age-matched MSCs [27].
These alterations are characterized by a lower proliferative
capacity, lower adipogenesis and chondrogenesis and
increased osteogenesis in OA-MSCs. These changes in
OA-MSCs can be attenuated or reversed by particular
supplementation of culture media [28]. This could explain
why in our in vitro cultures cell proliferation and
differentiation was quite similar.
Although the role of MSCs still remains unknown, and
the exact pathogenetic mechanisms of OA are unravelled,
the central role of WNT signaling pathway is considered
essential [6]. The Wnt signalling participates during
skeletogenesis and regulation of bone remodelling
processes in adult tissues through the expression of target
genes during endochondral ossification [29]. However, the
role of Wnt signalling in osteogenesis is by far controver-
sial. While some authors have reported that its activation
promotes osteogenesis [30, 31], others argued the
detrimental effects in osteogenesis upon Wnt activation
[32, 33]. Moreover, Liu et al. [34] recently described that
Wnt promoted the osteogenesis in normal medium
while inhibited it the osteogenic differentiation medium.
This dual effect was attributed to a regulatory loop
between miR-17 and its target (TCF3). Taken together,
these contradictory results suggest the critical effect of
experimental conditions or microenvironmental and
epigenetic factors rather than genetic differences. In this
regard, a recent report described that reduced methylation
in the osteoarthritic bone, compared to osteoporotic bone,
results in an upregulated expression of genes and
increased WNT pathway activity [35].
As occurs with other signalling pathways, regulation takes
place at different levels. Post-transcriptional regulation by
Fig. 3 miR-335-5p and MEST expression in OA-MSCs and
Control-MSCs. a. Box and wiskers plot of miR-335-5p expression in
OA-MSCs and Control-MSCs relative to the RNU6B internal control
gene. b. MEST expression in human in OA-MSCs and Control-MSCs
relative to the GAPDH reference gene. A positive correlation between
miR-335-5p and MEST expression was detected (Spearman
correlation coefficient, r = 0.59; p = 0.0961 in OA and r = 0.6;
p = 0.0968 in controls
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miRNAs have emerged as key modulators of signal
transmission and cellular response to extracellular signals
[36]. In this study we performed a comparative profiling of
miRNA expression during in vitro osteogenic differenti-
ation of BM-MSCs isolated from OA and Control subjects.
We aimed to describe a signature of miRNAs potentially
involved in the deregulated osteogenesis occurring in OA.
The role of miR-335-5p on Wnt signalling has been
described primarily in cancer. Its implication in bone
development has been only partially evidenced. At least
30 genes, related or belonging to the Wnt pathway, have
been previously described with varying degrees of
evidence as validated targets of this miRNA [17, 37–40]
(Table 2). In our study, after filtering of 754 initially
screened miRNAs and further validation of 21 of them,
only hsa-miR-210 and hsa-miR-335-5p showed significa-
tive differences in expression during osteogenesis.
Subsequently, using the latest miRTarBase database, we
analyzed if these miRNAs showed experimentally validated
miRNA-target interactions in the Wnt pathway. Given that
only miR-335-5p showed the existence of direct potential
targets we focused our attention on this miRNA.
(Additional file 6).
In the present study, we have demonstrated the
existence of a downregulation of miR-335-5p in OA-
MSCs compared to Control-MSCs. Moreover, we
demonstrated the existence of a similar and progressive
downregulatory trend of this miRNA along the osteogenic
differentiation Control-MSCs not significant in the case of
OA-MSCs. Decreased expression of Wnt antagonists such
as DKK1 and SFRP1 are likely a major cause of increased
Wnt/β-catenin signalling. In this particular, expression of
miR-335-5p has been previously described as a key regula-
tor of bone development promoting the downregulation of
DKK1 at initial stages of osteogenesis [17]. This modulatory
effect significantly persist at later stages of osteogenesis in
Control-MSCs, likely to prevent excessive mineralization
by promoting elevated levels of DKK1 and/or SFRP1
through dowregulation of miR-335-5p. Although post-
transcriptional regulation by miRNAs usually results in
gene silencing by reduction of translation and mRNA
levels, we found that miR-335-5p did not exert this
inhibitory effect on DKK1 or SFRP1 mRNA levels. This
result, however, is consistent with evidences suggesting that
under particular conditions, such as stress, inhibition of
translation initiation and mRNA stabilization can occur
simultaneously [41].
Previous observations of Tomé et al. [20] proposed the
key regulatory role of miR-335 in MSCs biology, conclud-
ing that upregulation of miR-335 impairs the MSC
reparative phenotype. Here we provide new insights about
the putative role of miR-335 in Wnt signalling throughout
osteogenesis in OA pathology suggesting a more active
Wnt signalling and thus increased osteogenesis and
mineralization in OA. In addition to the modulatory role of
WNT pathway by miR-335-5p, several other genes involved
Fig. 4 Two percent agarose gel of DKK1 and SFRP amplification products from OA-MSCs and Control-MSCs. After synthesizing the first strand
cDNA, it was amplified using PCR. The PCR product was analyzed by agarose gel electrophoresis. PCR reactions (25ul) were loaded as follow:
Lanes [1–6] ACTB [8–13] DKK1. [15–20] ACTB + SFRP1. Lanes 7 and 14 correspond to the molecular markers (GeneRuler™ Low Range DNA Ladder,
Fermentas). This result shows that single specific PCR product was obtained with expected molecular amplicon sizes. No differences were found
in band intensity between OA-MSCs and Control-MSCs
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in extracellular matrix formation have been also described
as targets of this miRNA, in particular collagen genes. Some
of them, previously described by our group, were clearly
downregulated in OA-MSCs. In particular COL10A1 [42].
Conclusions
Collectively, these evidences indicate the existence of a
correlation between miR-335-5p expression and OA
indicating a putative role of this miRNA. These features
are of particular interest given that subchondral and
periarticular bone remodelling as well as establishment
of a proper subchondral cartilage plays a role in the
progression of osteoarthritis (OA). These data contribute
to our understanding of the molecular mechanisms
involved in MSCs mediating homeostatic control in OA
pathophysiology.
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